Seizure and Prison for Owner of Immuno Biotec
Recommendation
7/8 May 2024
How to foster Continual Quality Improvement
Register now for ECA's GMP Newsletter
After a four-year investigation by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) (and with the support of the London Regional Asset Recovery Team, RART), the owner of Guernsey-based Immuno Biotech is now facing a £1.4 million seizure, including private property.
He has already served a 15-month prison sentence based on four counts of manufacturing, selling and supplying an unlicensed drug (plus one for money laundering).
Immuno Biotech was a distributor of a human blood product called Globulin component Macrophage Activating Factor (GcMAF). GcMAF was advertised and sold over the Internet as a so-called "miracle cure" for various diseases and conditions. Following an investigation, the MHRA confiscated more than 10,000 vials of the product and issued a warning to the public.
Source: GOV.UK provided by the Government Digital Service.
Related GMP News
21/02/2024
GMP Conferences by Topics
- General Quality Assurance and GMP Compliance Topics
- Hygiene
- General Microbiology Topics
- Regulatory Affairs
- Development
- General Analytics Topics
- Good Distribution Practice
- Sterile Manufacturing
- Computer Validation
- General Qualification/Validation Topics
- General Engineering Topics
- APIs/Excipients
- GMP Basic Training Courses
- Medical Devices and Combination Products
- Packaging and Packaging Material
- Data Integrity
- Qualified Person (QP)
- GMP Auditing
- Documentation
- Cleaning Validation
- General IT Compliance Topics
- Impurities
- OOS / OOE / OOT
- Material Testing
- Validation of Analytical Methods
- Analytical Instrument Qualification
- Stability Testing
- Microbiological Testing
- Technology
- General Manufacturing Topics
- Solid Dosage Forms/Semi-Solid Dosage Forms
- Biotechnology/Blood/ATMP
- Herbal Drug Products/Cannabis/Radiopharmaceuticals
- Others